Accession Number:

ADA244837

Title:

ASTPHLD Annual Conference on Human Retrovirus Testing (6th) Held in Kansas City, Missouri on March 5 - 7, 1991

Descriptive Note:

Final proceedings rept. 1 Feb 1991-31 Jan 1992,

Corporate Author:

ASSOCIATION OF STATE AND TERRITORIAL PUBLIC HEALTH LAB DIRECTORS WASHINGTON DC

Personal Author(s):

Report Date:

1992-01-31

Pagination or Media Count:

84.0

Abstract:

The constant evolution of testing methodologies for the human retroviruses demands that periodic reviews of the capabilities of these methodologies used in the public health laboratories be conducted. The following are descriptions of the six panel sessions concentrating on the most relevant topics of human retrovirus testing. Panel Session 1 was entitled Testing for HIV-1. Topics discussed included rapid testing methods, Western blots, testing of non traditional samples, surrogate markers, recombinantsynthetic based assays, Western blot interpretation criteria, indirect fluorescent antibody methods, and viral detection methods. Panel Session 2, entitled Polymerase Chain Reaction, discussed methodologies used in PCR, quality assurance, proficiency testing, and test interpretation and reporting. Panel Session 3 centered on developments within Flow Cytometry. The topics covered flow cytometry for disease staging, monitoring anti viral therapy, training, quality assurance, reporting criteria, and interpretation. Panel Session 4 addressed Testing for HIV-2 and HTLV-I HTLV-II. Topics covered HTLV-I and HTLV-II differentiation, the confirmation methodologies and criteria for HIV-1 and HIV-2 as opposed to HTLV-III viruses, HIV-1 and HIV-2 combination tests and alternate rapid testing methods. Panel Session 5 concentrated on The Diagnosis of HIV infection in Newborns. The topics covered, in a very specific sense, the use of flow cytometry, PCR, and viral culture to enhance detection of infection in newborns. Discussions also covered the use of ELISPOT , in vitro assays and analysis for IgA.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE